Guggenheim Downgrades Keros Therapeutics (NASDAQ:KROS) to Neutral

Guggenheim cut shares of Keros Therapeutics (NASDAQ:KROS) from a buy rating to a neutral rating in a research report report published on Monday, MarketBeat reports.

KROS has been the topic of a number of other research reports. BTIG Research downgraded Keros Therapeutics from a “buy” rating to a “neutral” rating in a report on Thursday, December 12th. Wedbush reissued an “outperform” rating and set a $84.00 price target on shares of Keros Therapeutics in a research report on Thursday, November 7th. Cantor Fitzgerald reissued an “overweight” rating on shares of Keros Therapeutics in a report on Friday, November 22nd. Bank of America dropped their target price on shares of Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating on the stock in a research note on Thursday, September 12th. Finally, TD Cowen cut Keros Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Four research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to MarketBeat.com, Keros Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $81.33.

Keros Therapeutics Trading Down 4.8 %

KROS opened at $17.13 on Monday. The stock has a 50-day moving average price of $56.64 and a 200-day moving average price of $52.06. The stock has a market capitalization of $693.88 million, a P/E ratio of -3.29 and a beta of 1.20. Keros Therapeutics has a 12-month low of $15.67 and a 12-month high of $73.00.

Keros Therapeutics (NASDAQ:KROS) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.28) by ($0.13). Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The business had revenue of $0.39 million for the quarter. During the same period last year, the firm posted ($1.33) EPS. The firm’s revenue for the quarter was up 4750.0% on a year-over-year basis. On average, equities research analysts predict that Keros Therapeutics will post -5.26 EPS for the current year.

Institutional Investors Weigh In On Keros Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the stock. SG Americas Securities LLC bought a new stake in Keros Therapeutics during the 2nd quarter valued at approximately $532,000. Assenagon Asset Management S.A. purchased a new stake in Keros Therapeutics during the second quarter valued at approximately $1,118,000. Bank of New York Mellon Corp raised its holdings in Keros Therapeutics by 18.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 118,388 shares of the company’s stock valued at $5,410,000 after buying an additional 18,755 shares during the period. Rhumbline Advisers lifted its holdings in shares of Keros Therapeutics by 20.6% in the 2nd quarter. Rhumbline Advisers now owns 41,638 shares of the company’s stock worth $1,903,000 after acquiring an additional 7,111 shares during the last quarter. Finally, Arizona State Retirement System lifted its stake in Keros Therapeutics by 16.3% in the second quarter. Arizona State Retirement System now owns 8,077 shares of the company’s stock worth $369,000 after purchasing an additional 1,130 shares during the last quarter. 71.56% of the stock is currently owned by hedge funds and other institutional investors.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.